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ABSTRACT 
Objective: This study aimed at developing a simple and rapid high-performance liquid chromatography (HPLC) method for determination of two 
thiazolidinedione derivatives, which were developed as anti-proliferative moieties (CSR1 and CSR2) in rat plasma. In addition, their oral 
pharmacokinetics were studied. 
Methods: Drugs were recovered from plasma using acetonitrile and analyzed on a Kromasil C8 column (250 mm × 4.6 mm; 4 μm). HPLC running 
conditions (0.01M phosphate buffer [pH = 3.0]; flow rate, 0.9 ml/min; at 210 nm; run time, 17 min) were optimized and further used for the 
determination of pharmacokinetic parameters. 
Results: At the described chromatographic conditions, CSR1, CSR2 and internal standard (metformin) eluted at 10.44, 9.41, and 3.15 min, 
respectively. The calibration curves were linear over the range of 0.25–20 µg/ml, with a correlation coefficient>0.999. The quantification limit was 
0.25 µg/ml. Within- and between-day precision values were less than 15%. The developed HPLC method was successfully used to study the 
pharmacokinetics of CSR1 and CSR2 in rats. The developed method was successfully used to study the pharmacokinetics of CSR1 and CSR2. Cmax, 
AUC0-12, Tmax, t1/2 for CSR1 were 12.2±1.9 µg/ml, 65.34±0.12 µg h/ml, 4.07±0.23 h, t1/2= 4.54±0.12 h, respectively, and those for CSR2 were 
10.6±2.2 µg/ml, 62.45±0.31 µg h/ml, 3.56±0.23 h, 3.86±0.09 h, respectively. 
Conclusion: A specific, linear, and reproducible method was successfully developed and implemented to determine pharmacokinetic activity for 
two thiazolidinedione derivatives (CSR1 and CSR2), which have been shown to have significant anti-proliferative activity.  
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INTRODUCTION 
The thiazolidinedione (TZD) class of peroxisome proliferator 
activated receptor γ (PPARγ) ligands are predominantly known for 
their insulin sensitization activity and also exhibit anticancer 
activity. Although use of TZDs has been controversial owing to their 
marked side effects at diabetic doses, it is important to note that 
there is a 3-order magnitude discrepancy between the concentration 
required to mediate antitumor effects and that for PPARγ activation 
[1, 2]. The toxicities of TZDs have also been attributed to the full 
activation of the receptor that eventually activates the genes 
responsible for the effects [3]. As in previous studies on PPARγ 
agonists such as efatutazone (Daiichi Sankyo), telmisartan, 
netoglitazone, α-aryloxy-α-methyl hydroxy cinnamic acid, and α-
benzyl propionic acid derivatives, which were found to be effective 
against various cancer cell lines [4-6], we also prioritized on PPARγ 
agonism and fewer side effects when searching for novel PPARγ 
agonists. Thus, to overcome the toxicity issues related to full PPARγ 
agonists, we also reported novel TZDs and their bioisosteres, the 
oxazolone derivatives [2, 3]. These novel TZD molecules were 
designed by altering the structure of the well-known antidiabetic 
drug, pioglitazone. The TZDs synthesized and reported by us 
exhibited anticancer activity independently of PPARγ.  
Of the various synthesized derivatives, two TZD derivatives (CSR1 
and CSR2) (fig. 1) had potential anti-proliferative activity on breast 
cancer (MCF-7), oral cancer (GURAV), and chronic myeloid leukemia 
cell lines (K-562), with GI50 values ranging from 0.23 to 65μM. The 
antiproliferative potential of both the molecules was higher on the 
K-562 cell lines, with GI50 values of 0.9 μM (CSR1) and 0.23μM 
(CSR2) [7]. Moreover, both molecules arrested the cell cycle in the 
G0/G1 phase at a concentration of 10 μM. Furthermore, both 
molecules reduced cyclin D1 and proliferative cell nuclear antigen 
(PCNA) levels in a dose-and time-dependent manner, as determined 
using SDS PAGE analysis (data not published). In vivo tumor 
























Fig. 1: Chemical structures of CSR1 and CSR2 
 
Pre-clinical pharmacokinetic characteristics can help predict drug 
behavior. However, CSR1 and CSR2 pharmacokinetics have not been 
reported. Therefore, we developed a robust assay for 
pharmacokinetic study of CSR1 and CSR2.  
In this study, we developed a high-performance liquid chromate-
graphy (HPLC) method using rat plasma; furthermore, 
representative plasma concentration versus time profiles of CSR1 
and CSR2 are presented in this paper.  
MATERIALS AND METHODS 
Chemicals and reagents 
CSR1 and CSR2 were synthesized as per reported scheme [8]. The 
synthesized compounds were purified by recrystallization with ethanol 
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and characterized by 1H NMR, 13C NMR and mass spectrometry. 
Metformin (Supplier: Aarti Drugs Ltd., India; Batch No.: MET/14090518) 
was provided as a gift sample by Meyer Organics (Mumbai, India). HPLC 
grade acetonitrile and methanol were obtained from SD Fine Chemicals. 
Analytical grade diethyl ether and ethyl acetate were purchased from 
Thermo Fisher Scientific India Pvt. Ltd.  
Animals and diet 
Male Wistar rats weighing 150-170 g (National Institute of Nutrition, 
Hyderabad, India), were housed in a temperature-controlled (21±2 
°C) room with 12 hour light-dark cycle. The experimental protocol 
was approved by Institutional Animal Ethical Committee as per the 
guidance of Committee for Purpose of Control and Supervision of 
Experiments on Animals (CPCSEA) (IAEC/PR/2014-2015/03), 
Ministry of Forest and Environment, Government of India, New 
Delhi, India. Prior to the experiment, rats were acclimatized for at 
least one week. During the acclimatization and study period, animals 
were maintained on normal chow diet.  
Instrumentation 
The HPLC system used was HPLC Shimadzu LC-2010C HT, series 
equipped with a 0.1 to 100 μl sample loop, and LC-100 UV detector 
and a PDA detector. The output signal was monitored and integrated 
using LC Solution® version 1.2 software. 
Chromatographic conditions 
Chromatographic separation was achieved using a Kromasil C8 
column (250 mm × 4.6 mm; 4 μm particle size). The method 
involved use of 0.01M phosphate buffer (A) with a pH 3.0, adjusted 
with orthophosphoric acid and acetonitrile (B) as mobile phase. The 
mobile phase was prepared by initially passing through a 0.45 μm 
filter followed by ultrasonication for 15 min. The gradient program 
was (Time/%B)–0/2, 5/70, 10/98, 13/2, 17/2, with 0.9 ml/min flow 
rate 20 μl as sample volume. Detection was performed at 210 nm.  
Standard solutions 
CSR1, CSR2, metformin (IS) standard solution were prepared by 
dissolving 10 mg of drug in 10 ml methanol to give a final 
concentration of 1000 µg/ml. A serial dilution was carried out for 
CSR1 and CSR2 to give 0.25, 0.5, 1, 2, 5, 10 and 20 µg/ml standard 
solutions. Stock solution of IS was diluted to achieve a final 
concentration of 50 µg/ml.  
Sample preparation  
Ten microliter of standard solutions of CSR1, CSR2 and metformin 
(internal standard) were spiked to a 70 μl of plasma sample in a 
microcentrifuge tube and vortex mixed for 5 seconds. Later on, as 
determined from recovery studies, 900 μl of acetonitrile was added for 
liquid-liquid extraction. The microcentrifuge tubes were then vortex 
mixed for 40 seconds and centrifuged at 4000 rpm for 10 min. The 
supernatant was transferred to a microcentrifuge tube and was 
evaporated to dryness using nitrogen gas. The dried microcentrifuge 
tubes which contained the extracted drugs were reconstituted with 
100 μl of mobile phase of which 20 μl was used for analysis. For 
pharmacokinetic studies, the same procedure was followed, and 20 μl 
of reconstituted supernatant was injected to HPLC system. 
Method validation 
Calibration curve and lower limit of quantification (LLOQ) 
Calibration curve was obtained by spiking series of standard 
solutions of CSR1 and CSR2 (0.25, 0.5, 1, 2, 5, 10 and 20 µg/ml) along 
with IS in rat plasma. The lowest concentration of the analyte that 
gives at least 5 times the response as compared with a blank was 
considered as the Lower Limit of Quantification (LLOQ). The drugs 
were extracted as described in sample preparation method. The 
procedure was repeated three times for the said chromatographic 
method. The peak areas ratios of CSR1 and CSR2 to IS (Y axis) were 
plotted against the corresponding concentrations (X axis).  
Recovery studies 
To determine highest recovery of drug in a particular solvent after 
protein precipitation, four different solvents were used i.e. 
acetonitrile, diethyl ether, ethyl acetate and methanol. A typical set 
for each solvent consisted of a zero sample (plasma with IS) and 
plasma sample spiked with CSR1 and CSR2 at three different 
concentrations (0.5, 5 and 20 µg/ml) and metformin (IS) (50 µg/ml). 
Ten microliter of CSR1 and CSR2 standard solutions and 10 μl of IS 
solution were added to a 70 μl of plasma sample in a microcentrifuge 
tubes. Liquid-liquid extraction was performed according to the 
method described for sample preparation. Reconstituted 20 μl of 
sample from respective sets of solvent was injected into the HPLC 
system. The experiment was performed in triplicate. The peak areas 
ratios of CSR1 and CSR2 to IS were compared among various 
solvents used.  
Accuracy and precision 
Accuracy and precision of this method was established by within-
day and between-day analysis. Three different concentrations (0.25, 
2 and 20 µg/ml) of CSR1 and CSR2 were assayed on six consecutive 
days. The procedure was repeated three times for the said 
concentrations of CSR1 and CSR2. 
Sample collection 
To test the applicability of bioanalytical method developed, the 
plasma concentration of CSR1 and CSR2 was measured in rat 
plasma after administration of a single oral dose of CSR1 (250 
mg/kg) and CSR2 (250 mg/kg) in overnight fasted animals. The 
dose of CSR1 and CSR2 was selected based on maximum 
tolerated dose (MTD) study. The CSR1 and CSR2 were found to 
be safe up to 2500 mg/kg and one-tenth of MTD dose was used 
to study pharmacokinetic data. Suspensions of CSR1 and CSR2 
were freshly prepared in 1% w/v sodium carboxymethyl 
cellulose (CMC-Na).  
Blood samples were collected by retro-orbital puncture into 
microcentrifuge tubes containing heparin at 0, 0.25, 0.5, 1, 2, 4, 6, 8 
and 12 h following drug administration. The study was carried out 
by sparse sampling design using three rats for each time point. 
Blood samples were centrifuged at 2000 g for 10 min, and plasma 
samples were separated and stored at–20 °C until analysis.  
RESULTS AND DISCUSSION 
Chromatography conditions 
Various mobile phases and columns were tested to determine CSR1 and 
CSR2. The best result was obtained using a Kromasil C8 column and 
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Fig. 2: Chromatogram of A) Blank sample (plasma without IS); 
B) A zero sample (plasma with IS); C) Plasma spiked with CSR1 
(0.25 µg/ml) and D) Plasma spiked with CSR1 (20 µg/ml) E). 
Plasma spiked with CSR2 (0.25 µg/ml) F) Plasma spiked with 
CSR2 (20 µg/ml) 
 
Metformin was chosen as the IS, given the suitable retention time 
and adequate recovery. Under the chromatographic conditions 
described, metformin, CSR1, and CSR2 eluted at 3.15, 10.44, and 9.41 
min, respectively. The proposed method was found to be suitable for 
quantification of CSR1 and CSR2 in plasma samples. Chromatograms 
obtained for the blank sample (plasma without IS), zero sample 
(plasma with IS), and plasma samples spiked with CSR1, CSR2, and 
IS at lowest and highest concentrations are presented in fig. 2. 
A comparison of the chromatogram of the independent blank plasma (A) 
with that of internal standard (B) and lower limit of quantification of 
CSR1 and CSR2 (C, D, E and F) illustrates the specificity and selectivity of 
the method. The baseline was relatively free from drift.  
Calibration curve and lower limit of quantification (LLOQ) 
Calibration curves were constructed using seven series of plasma 
samples spiked at concentration levels in the range of 0.25-20 
µg/ml. A linear relationship was obtained between the peak area 
ratios of individual drugs to those of the internal standard at the 
corresponding concentration, as shown by the equation in fig. 3. 
The LLOQ was found to be 0.25 μg/ml, with a coefficient of 
variation (CV) of 10.72%. The linearity of the calibration curve for 
both CSR1 and CSR2 was validated by the high value of the 
correlation coefficient (R2=0.999). The typical standard curve was 
described using the equation y= 0.0188x+0.0106 for CSR1 and 
y=0.0183x+0.0071 for CSR2, where y is the peak area and x is the 
concentration. According to the Food and Drug Administration 
(FDA) guidelines, the deviation for the calculated concentrations 
from the nominal concentration should be within 15%, with an 
exception of 20% for LLOQ. The accuracy and precision of 
calculated values at each nominal concentration in this study were 




Fig. 3: The calibration curves of CSR1 and CSR2 in rat plasma 
 
Recovery studies 
Liquid–liquid extraction of CSR1 and CSR2 was performed using 
various solvents. Maximal recover was obtained using acetonitrile. 
The mean±SD recovery of CSR1 at 0.5, 5, and 20 µg/ml was found to 
be 90.21±2.2%, 92.53±2.5%, and 97.78±1.3%, respectively. 
Similarly, the mean±SD recovery of CSR2 at 0.5, 5, and 20 µg/ml was 
found to be 89.23±2.1%, 94.88±2.4%, and 98.21±2.3%, respectively. 
The mean±SD recovery of the IS at 50 µg/ml was 98.26±2.2% (table 
1). The recoveries at all the three concentrations were consistent, 
precise, and reproducible, indicating the suitability of the liquid 
extraction procedure for separation of CSR1 and CSR2 from rat 
plasma. 
Accuracy and precision  
The accuracy and precision values were determined by using 
calibration standard curve of CSR1 and CSR2 at 0.25, 2, and 20 
µg/ml in plasma on six consecutive days. Within-and between-day 
results are shown in table 2 with CV values<11.3% and<10.4 for 
CSR1 and CSR2 respectively. The error (Er) was also found to 
be<1.84% and<1.83% for CSR1 and CSR2 respectively. The 
accuracies and precisions for the tested levels were all within the 
defined acceptance criteria, demonstrating that the method was 
accurate and precise. 
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Table 1: Recovery study of CSR1 and CSR2 
Concentration (µg/ml) CSR1 (%) CSR2 (%) 
0.5 90.21±2.2 89.23±2.1 
5 92.53±2.5 94.88±2.4 
20 97.78±1.3 98.26±2.2 
 N=3, values are expressed in mean±SD 
 
Table 2: Precision and accuracy estimation of CSR1 and CSR2 in spiked plasma 
 CSR1 CSR2 
Concentration added (µg/ml) Concentration found (µg/ml) CV (%) Er (%) Concentration found (µg/ml) CV (%) Er (%) 
Within-day  
0.25 0.258±0.008 11.34 1.84 0.257±0.006 10.49 1.83 
2 1.960±0.073 3.53 1.03 1.762±0.037 1.76 0.98 
20 20.086±0.713 5.23 0.98 19.965±0.346 3.41 1.02 
Between-day (n=18) 
0.25 0.248±0.009 10.09 1.23 0.252±0.004 8.36 1.11 
2 1.947±0.078 1.56 0.92 1.876±0.065 1.24 0.89 
20 20.034±0.648 4.63 0.78 19.867±0.534 3.21 0.73 
Within day, N=3; Between-day, N = 18; Concentration found values are expressed in mean±SD; CV=coefficient of variation; Er= Error. 
 
Pharmacokinetic study 
The validated assay method was successfully used for oral 
pharmacokinetic study of CSR1 and CSR2 in rats. The average 
plasma drug concentration vs. time profile after a single oral 
administration of CSR1 and CSR2 (250 mg/kg) is shown in fig. 4. The 
pharmacokinetic parameters (mean±SD) for CSR1 are as follows: 
Cmax = 12.2±1.9µg/ml, AUC0-12 = 65.34±0.12 µg h/ml, Tmax = 
4.07±0.23 h, t1/2 = 4.54±0.12 h; those for CSR2 are as follows: Cmax = 
10.6±2.2 µg/ml, AUC0-12 = 62.45±0.31 µg h/ml, Tmax = 3.56±0.23 h, 
t1/2 = 3.86±0.09 h. As mentioned earlier, the molecular design of each 
of our synthesized molecules (CSR1 and CSR2) resembles that of 
pioglitazone. Fujita et al. reported the following pharmacokinetic 
parameters of pioglitazone in male rats after single oral 
administration at 10 mg/kg: Tmax =2.8±1.1 h, Cmax = 13.6±1.9 
μg/ml, and t1/2 = 2.5±0.4 [9]. Evidently, our molecules have a similar 
pharmacokinetic profile. Some differences in the values could be due 
to the structural modifications.  
 
Fig. 4: Mean±SD of plasma concentration-time curve following 




We developed a simple and rapid HPLC method for 
quantification of CSR1 and CSR2 in rat plasma. All results were 
within the acceptable range, and clear separation of the 
compounds and IS, without interfering peaks, was obtained. The 
assay was validated and standard curves were linear over the 
concentration ranges investigated. The developed method was 
successfully applied for the analysis of plasma samples from rats 
for pre-clinical pharmacokinetic studies. This study provides 
with a better understanding of the pharmacological features of 
our CSR1 and CSR2, which will be helpful in further 
development.  
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